Phan K, et al. - In nonrenal transplant recipients, researchers evaluated the impacts of mammalian target of rapamycin (mTOR) inhibitors on secondary nonmelanoma skin cancer (NMSC) malignancies. Eligible studies for this systematic review and meta-analysis included those in which patient cohorts underwent heart, liver, lung, and pancreas (ie, nonrenal solid organ) transplantation, with the treatment group being those treated with an mTOR inhibitor such as sirolimus or everolimus, and control group being placebo, or alternative non-mTOR inhibitor treatment such as calcineurin inhibitors or as per standard treatment protocol. Findings suggested that mTOR inhibitors might have a protective effect against secondary NMSC but not primary NMSC posttransplantation in nonrenal transplant recipients. Caution should be given to extrapolating the findings of reduced NMSC in populations of renal transplants to cases of nonrenal transplants.